Abstract
O veractive bladder is a common and distressing disorder characterised by the urinary symptoms of urgency, frequency and urge incontinence. Tolterodine * is a new antimuscarinic drug developed specifically for the treatment of this condition. Given that overactive bladder has a marked effect on patient quality of life (QOL), the beneficial effects of tolterodine on the QOL of patients with this condition, together with the economic implications of treatment, were key issues discussed at a Pharmacia & Upjohn-sponsored symposium ** held at the 93rd Annual Meeting of the American Urological Association [ San Diego, US; May 1998 ].
This is a preview of subscription content, log in via an institution to check access.
Additional information
* ‘Detrusitol’, ‘Detrol’; Pharmacia & Upjohn
** The symposium was entitled ‘A New Pharmacological Alternative for the Management of Overactive Bladder’.
Rights and permissions
About this article
Cite this article
Clemett, D. Tolterodine. Pharmacoecon. Outcomes News 173, 3–4 (1998). https://doi.org/10.1007/BF03284929
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03284929